CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 143 enrolled
Drug / intervention
Oxybutynin chloride, extended-release +1 moredrug
Likely dose
Oxybutynin chloride, extended-release 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01187498
NCT01187498Phase 3Completed
CompareCT.gov

Behavioral Treatment of Overactive Bladder in Men

US Department of Veterans Affairs·interventional·Posted Aug 24, 2010·Updated May 20, 2014

In Brief

A Phase 3 clinical trial evaluating Behavioral training and Oxybutynin chloride, extended-release for Overactive Bladder. Completed, enrolled 143 participants across 2 sites.

Detailed Summary

The primary purpose of this project is to evaluate the effectiveness of behavioral treatment compared to standard drug therapy for symptoms of OAB in male veterans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2010
Enrollment StartJan 1, 2005
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.9 years ago

Interventions

Behavioral trainingbehavioral

Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.

Oxybutynin chloride, extended-releasedrug

Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.